Subscribe

Deyaa Adib, MD

Articles by Deyaa Adib, MD

Deyaa Adib, MD

Deyaa Adib, MD, on Optimizing Manufacturing of Solid Tumor Cell Therapies

ByDeyaa Adib, MD

October 13th 2022

The chief medical officer of Triumvira Immunologics discussed the company’s future plans.

Deyaa Adib, MD

Deyaa Adib, MD, on Safety Advantages of TAC T-Cell Therapy in Solid Tumors

ByDeyaa Adib, MD

September 26th 2022

The chief medical officer of Triumvira Immunologics discussed how TAC01-HER2 could address unmet needs in treating solid tumors.

Deyaa Adib, MD

Deyaa Adib, MD, on Evaluating HER2 TAC T-Cell Therapy in Solid Tumors

ByDeyaa Adib, MD

September 22nd 2022

The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.

Deyaa Adib, MD, on Targeting HER2 in Solid Tumors With the TAC Platform

ByDeyaa Adib, MD

July 25th 2022

The chief medical officer of Triumvira Immunologics discussed promising early results from the company’s phase 1/2 clinical trial.

Deyaa Adib, MD, on Using T-Cell Antigen Coupler Technology to Target Solid Tumors

ByDeyaa Adib, MD

July 23rd 2022

The chief medical officer of Triumvira Immunologics discussed the company’s TAC platform and its versatile target-recognizing domain.

Latest Updated Articles

Deyaa Adib, MD, on Evaluating HER2 TAC T-Cell Therapy in Solid Tumors
Published: September 22nd 2022 | Updated:
Deyaa Adib, MD, on Optimizing Manufacturing of Solid Tumor Cell Therapies
Published: October 13th 2022 | Updated:

Trending on CGTlive®

Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial

Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation

Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025

FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program

BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again

© 2025 MJH Life Sciences^®

All rights reserved.